UBS AM’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.67M | Buy |
83,054
+47,156
| +131% | +$946K | ﹤0.01% | 2220 |
|
|
2025
Q1 | $706K | Sell |
35,898
-7,816
| -18% | -$154K | ﹤0.01% | 2423 |
|
|
2024
Q4 | $984K | Buy |
43,714
+17,546
| +67% | +$395K | ﹤0.01% | 2369 |
|
|
2024
Q3 | $668K | Buy |
26,168
+2,944
| +13% | +$75.2K | ﹤0.01% | 2558 |
|
|
2024
Q2 | $543K | Buy |
+23,224
| New | +$543K | ﹤0.01% | 2606 |
|